# EDGAR Filing Document

**Accession Number:** 0001660334
**File Stem:** 0001193125-25-326765
**Filing Date:** 2025-12
**Character Count:** 2522
**Document Hash:** 57d1e27191be3700afdca92ff27a7571
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-326765.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001193125-25-326765

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Verrica Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001660334
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 463137900
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 44 WEST GAY STREET
- **STREET 2:** SUITE 400
- **CITY:** WEST CHESTER
- **STATE:** PA
- **BUSINESS PHONE:** 484-453-3300

**MAIL ADDRESS:**
- **STREET 1:** 44 WEST GAY STREET
- **STREET 2:** SUITE 400
- **CITY:** WEST CHESTER
- **STATE:** PA

**Verrica Pharmaceuticals Inc.** 

**44 W. Gay St. Suite 400** 

**West Chester, PA 19380** 

December 19, 2025

**<u>VIA EDGAR</u>**

Division of Corporation Finance

Office of Technology

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **RE:** | **Verrica Pharmaceuticals Inc.**  |

---

**Registration Statement on Form S-3** 

**File No. 333-292140** 

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, Verrica Pharmaceuticals Inc. (the "**Registrant**") hereby requests that the U.S. Securities and Exchange Commission (the "**Commission**") take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on December 23, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Mark Ballantyne and Divakar Gupta of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Mark Ballantyne at (703) 456-8084, or in his absence, Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474.

---

| | |
|:---|:---|
|  Very truly yours, | Very truly yours, |
| **VERRICA PHARMACEUTICALS INC.** | **VERRICA PHARMACEUTICALS INC.** |
| By: | /s/ David Zawitz |
| Name: | David Zawitz |
| Title: | Chief Operating Officer |

---

cc: Mark Ballantyne, Cooley LLP

Divakar Gupta, Cooley LLP